share_log

科伦药业:关于子公司核心产品芦康沙妥珠单抗(sac-TMT)于2024年美国临床肿瘤学会年会上公布研究成果的公告

Sichuan Kelun Pharmaceutical: Announcement on the subsidiary's core product, lucan satuzumab (sAC-TMT), announcing research results at the 2024 American Society of Clinical Oncology Annual Meeting

SZSI ·  May 23
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more